Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Dec 17, 2025
- Closes
- Jan 7, 2028 (in 450 days)
Similar opportunities open now
- Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)Same funderOpenNational Institutes of HealthCloses Oct 2027
- Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Jan 7, 2027 (in 85 days)
- Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Jan 2028
- Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 2027
- Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Jan 2028
Classification and identifiers
- Solicitation number
- PAR-25-145
- Assistance listing (CFDA)
- 93.393
Amount
Amount not listed here. Check the official program.
Who can apply
Local government agencies and Nonprofits, including small and volunteer-run organizations can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
About this opportunity
The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combin...